Research Topics
Species | Mack RoachSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?Mack Roach
UCSF Helen Diller Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94143 1708, USA
J Natl Cancer Inst Monogr 2012:221-9. 2012..In addition, a number of important evidence-based conclusions concerning what should and should not be done can be gleaned from these trials...- Successful radiation treatment of anaplastic thyroid carcinoma metastatic to the right cardiac atrium and ventricle in a pacemaker-dependent patientTina Dasgupta
Department of Radiation Oncology, 1600 Divisadero Street, Suite H1031, San Francisco, California 94102 1708, USA
Radiat Oncol 6:16. 2011.... 
Radiation dose-volume effects and the penile bulbMack Roach
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, USA
Int J Radiat Oncol Biol Phys 76:S130-4. 2010..It is acknowledged that the penile bulb may not be the critical component of the erectile apparatus, but it seems to be a surrogate for yet to be determined structure(s) critical for erectile function for at least some techniques...
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trialMack Roach
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 69:79-87. 2007..To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4 *1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02...- Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directionsMack Roach
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
J Surg Oncol 103:587-601. 2011..We provide clinical data that demonstrate how these evolving strategies have the potential to transform treatment paradigms... - Predictive models in external beam radiotherapy for clinically localized prostate cancerMack Roach
Department of Radiation Oncology, University of California at San Francisco, San Francisco, California, USA
Cancer 115:3112-20. 2009..Cancer 2009;115(13 suppl):3112-20. (c) 2009 American Cancer Society... - Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610Mack Roach
Department of Radiation Oncology, University of California San Francisco, 1600 Divisadero St, Suite H1031, San Francisco, CA 94143 1708, USA
J Clin Oncol 26:585-91. 2008..This report summarizes long-term follow-up results... - Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancerMack Roach
Helen Diller Comprehensive Cancer Center, University of California San Francisco, CA 94143 1708, USA
Int J Radiat Oncol Biol Phys 78:1314-22. 2010..We used two large Phase III trials involving androgen deprivation therapy and external beam radiation therapy to assess the significance of a BST... - Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?Mack Roach
Department of Radiation Oncology and Urology, University of California San Francisco, UCSF Comprehensive Cancer Center, San Francisco 94143 1708, USA
Strahlenther Onkol 183:26-8. 2007..This review compares both approaches and the rationale for using both... - Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrence After Initial PPI for Prostate CancerCharles C Hsu
Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California Electronic address
Int J Radiat Oncol Biol Phys 85:370-7. 2013..To assess the feasibility of magnetic resonance imaging (MRI)-planned partial salvage permanent prostate implant (psPPI) among patients with biopsy-proven local recurrence after initial PPI without evidence of distant disease... - Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomyDaniel C Schiffner
Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143 1708, USA
Int J Radiat Oncol Biol Phys 67:610-9. 2007..The aim of this study was to measure interfraction prostate bed motion, setup error, and total positioning error in 10 consecutive patients undergoing postprostatectomy radiotherapy... - Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boostSiavash Jabbari
Department of Radiation Oncology, University of California San Francisco, School of Medicine, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 76:36-42. 2010..We studied the biochemical control (biochemical no evidence of disease [bNED]) and prostate-specific antigen (PSA) nadir achieved with contemporary PPI, and evaluated it against 3D-CRT and CPBRT... - Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapyTim Joseph
Department of Radiology, University of California San Francisco, San Francisco, CA 94143 0628, USA
Int J Radiat Oncol Biol Phys 73:665-71. 2009.... - Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406Jeff Michalski
Department of Radiation Oncology, Washington University Medical School, St Louis, MO 63110, USA
Int J Radiat Oncol Biol Phys 83:e363-70. 2012..Report of clinical cancer control outcomes on Radiation Therapy Oncology Group (RTOG) 9406, a three-dimensional conformal radiation therapy (3D-CRT) dose escalation trial for localized adenocarcinoma of the prostate... - Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA responseSiavash Jabbari
Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA
Int J Radiat Oncol Biol Phys 82:228-34. 2012..Here, we report our technique, PSA nadir, and acute and late toxicity with SBRT as monotherapy and post-EBRT boost for PCa using HDR brachytherapy fractionation... - Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen levelBarby Pickett
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143, USA
Int J Radiat Oncol Biol Phys 65:65-72. 2006..Recent studies have suggested that the treatment of low-risk prostate cancer yields similar results for patients treated with 3D-CRT or PPI... - Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?Mack Roach
Department of Radiation Oncology, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143 1708, USA
Cancer 109:213-20. 2007..In this article, the authors summarize arguments for incorporating additional pretreatment parameters and creating a new staging system for prostate cancer... - High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experienceSiavash Jabbari
Department of Radiation Oncology, University of California San Francisco, 94115, USA
Brachytherapy 8:339-44. 2009..In this report, we describe our technique and early experience with definitive HDR brachytherapy in patients post APR and pelvic EBRT... - Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10William U Shipley
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 64:1162-7. 2006.... - Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapyArjun Sahgal
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA94143, USA
Int J Radiat Oncol Biol Phys 72:247-54. 2008..To compare the urethral and prostate absolute and biologic effective doses (BEDs) for 131 Cs and 125 I prostate permanent implant brachytherapy (PPI)... - Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancerI Chow J Hsu
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, USA
Brachytherapy 4:202-6. 2005..This is a retrospective review of our experience using high-dose-rate (HDR) brachytherapy boost for prostate cancer... - Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and IIJeff M Michalski
Department of Radiation Oncology, Washington University, St Louis, MO 63110, USA
Int J Radiat Oncol Biol Phys 56:192-8. 2003..To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406... - An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactionsColleen A Lawton
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
Int J Radiat Oncol Biol Phys 69:646-55. 2007..This trial was also designed to test the hypothesis that neoadjuvant hormonal therapy (NHT) followed by concurrent total androgen suppression and RT improves PFS compared with RT followed by adjuvant hormonal therapy (AHT) by > or =10%... - Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapyStephen L Shiao
Department of Radiation Oncology, University of California, San Francisco, CA, USA
Phys Med Biol 56:7767-75. 2011..21). We concluded that non-isocentric small-field Cyberknife delivery produced consistent biological dosing that tracked well with the constant-dose-rate, large-field-type delivery for prostate stereotactic body radiotherapy... - Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trialsDaniel A Hamstra
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109 5010, USA
Int J Radiat Oncol Biol Phys 81:1293-301. 2011.... - Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trialMack Roach
University of California San Francisco, San Francisco, CA 94143 1708, USA
Int J Radiat Oncol Biol Phys 66:647-53. 2006..To avoid a timing bias, this analysis was limited to patients receiving neoadjuvant and concurrent hormonal therapy (N&CHT) in Arms 1 and 2 of the study... - Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trialsMack Roach
Department of Radiation Oncology, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1708, USA
J Urol 169:245-50. 2003..We noted no evidence that race has independent prognostic significance in patients treated for prostate cancer in Radiation Therapy Oncology Group prospective randomized trials... - Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experienceBrian Lee
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94115, USA
Int J Radiat Oncol Biol Phys 67:1106-12. 2007..The aim of this study was to evaluate the feasibility and safety of salvage high-dose-rate (HDR) brachytherapy for locally recurrent prostate cancer after external beam radiotherapy (EBRT)... - Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time trackingDale W Litzenberg
Department of Radiation Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
Int J Radiat Oncol Biol Phys 68:1199-206. 2007..Ideally, the distances between transponders remains constant over the course of treatment. In this work, we evaluate the accuracy of these conditions... - Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancerLinda W Chan
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94115, USA
Int J Radiat Oncol Biol Phys 72:69-77. 2008..The purpose of this study was to develop these constraints, demonstrate that they are achievable, and assess the corresponding rectal toxicity... - Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IVJeff M Michalski
Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA
Int J Radiat Oncol Biol Phys 58:735-42. 2004..This is the first report of the toxicity outcomes using dose level IV (74 Gy) on Radiation Therapy Oncology Group (RTOG) study 9406 for Stage T1-T2 prostate adenocarcinoma... - Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancerBarby Pickett
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 60:1047-55. 2004.... - Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level VJeff M Michalski
Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
Int J Radiat Oncol Biol Phys 62:706-13. 2005..This is the first report of toxicity outcomes at dose Level V (78 Gy) on Radiation Therapy Oncology Group 9406 for Stages T1-T2 adenocarcinoma of the prostate... - Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapyDavid S Aaronson
Department of Urology, University of California, San Francisco, CA 94117, USA
BJU Int 104:600-4. 2009.... - An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodesErica Ludlum
Department of Radiation Oncology, University of California San Francisco, San Francisco, California 94143, USA
Med Phys 34:4750-6. 2007..0 cm. In order to concurrently treat the prostate and pelvic lymph nodes with the prostate moving independently, shifting selected MLC leaf pairs may be a more practical adaptive solution than shifting the patient... - High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemesTania Kaprealian
Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115, USA
Int J Radiat Oncol Biol Phys 82:222-7. 2012.... - Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceMack Roach
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
Int J Radiat Oncol Biol Phys 65:965-74. 2006..For example, if the median follow-up is 5 years, control rates at 3 years should be cited. Retaining a strict version of the ASTRO definition would allow comparisons with a large existing body of literature... - Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodesPing Xia
Department of Radiation Oncology, University of California San Francisco, San Francisco, California 94143, USA
Med Phys 37:5006-13. 2010..The purposes of this article are to propose a new management strategy and to compare this strategy to the conventional isocenter shift method and the previously proposed MLC-shifting method... - Prostate movement during simulation resulting from retrograde urethrogram compared with "natural" prostate movementYu-Ming Liu
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 60:470-5. 2004..64 mm, p = 0.004; anteroposterior = 2.24, p = 0.035). CONCLUSIONS: Use of the UG induces a small but clinically insignificant displacement of the prostate when "natural" movement is taken into account... - Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detectionAntonio C Westphalen
Department of Radiology, University of California San Francisco, 505 Parnassus Ave, Box 0628, M 372, San Francisco, CA 94143 0628, USA
Radiology 256:485-92. 2010..To determine if performing magnetic resonance (MR) spectroscopic imaging, compared with performing T2-weighted MR imaging alone, improves the detection of locally recurrent prostate cancer after definitive external beam radiation therapy... - Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapyJ Adam M Cunha
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94118, USA
Brachytherapy 11:348-53. 2012..This work describes a dose planning method that uses inverse planning to create a low-dose tunnel around the urethra and presents a class solution to achieve this additional dose sparing of the urethra... - Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experienceDavid A McKenna
Department of Radiology, University of California, San Francisco, M 372, 505 Parnassus Ave, San Francisco, CA 94143 0628, USA
Radiology 247:141-6. 2008..To retrospectively determine if pretreatment endorectal magnetic resonance (MR) imaging findings are predictive of outcome in patients who undergo external-beam radiation therapy for prostate cancer... - Technique for implantation of fiducial markers in the prostateKatsuto Shinohara
Department of Urology, University of California San Francisco and UCSF Mt Zion Comprehensive Cancer Center, San Francisco, California 94143 0711, USA
Urology 71:196-200. 2008..To describe our experience in developing a technique for implanting fiducial markers (gold markers and electromagnetic transponders) in the prostate by the transrectal approach under ultrasound guidance... - Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trialsMack Roach
Department of Radiation Oncology, Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94143, USA
J Urol 176:S16-20. 2006..We developed a model for determining disease specific survival in prostate cancer... - Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancerAlice Wang-Chesebro
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94115, USA
Int J Radiat Oncol Biol Phys 66:654-62. 2006.... - Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experienceFergus V Coakley
Department of Radiology, University of California San Francisco, 505 Parnassus Ave, Box 0628, M 372, San Francisco, CA 94143 0628, USA
Radiology 233:441-8. 2004..To evaluate endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging for the depiction of locally recurrent prostate cancer after external beam radiation therapy... - Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostateMack Roach
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, 94143-1708, USA
Urology 61:730-5. 2003..CONCLUSIONS: The pPSA level is an independent predictor of survival in patients initially treated with radiotherapy alone... - Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancerSabbir Hossain
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143 1708, USA
Int J Radiat Oncol Biol Phys 78:58-63. 2010..In particular, the dose gradient across the target and the critical structures such as the rectum and bladder was characterized... - Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation studyMack Roach
University of California San Francisco, San Francisco, CA 94143, USA
Int J Radiat Oncol Biol Phys 60:1351-6. 2004..To assess the relationship between the dose to the bulb of the penis and the risk of impotence in men treated on Radiation Therapy Oncology Group (RTOG) 9406... - Endorectal MRI after radiation therapy: questioning the sextant analysisShilpa R Kumbhani
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California 94143 0628, USA
J Magn Reson Imaging 33:1086-90. 2011..Despite its known limitations, sextant is the generally accepted standard for magnetic resonance imaging (MRI) and biopsy coregistration; nevertheless, depending on the magnitude of localization errors, other options may be adequate... - Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancerLaura Ellen Millender
Department of Radiation Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94143, USA
Int J Radiat Oncol Biol Phys 59:6-10. 2004..Setup error rather than organ motion appears to be the dominant force in positioning error in obese men... - Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI studyElnasif Arrayeh
Department of Radiology and Biomedical Imaging, University of California San Francisco, California, USA
Int J Radiat Oncol Biol Phys 82:e787-93. 2012.... - Megavoltage cone-beam CT: system description and clinical applicationsOlivier Morin
University of California San Francisco Comprehensive Cancer Center, Department of Radiation Oncology, 94143, USA
Med Dosim 31:51-61. 2006..Current image quality has already proven sufficient for many IGRT applications. Moreover, we expect the range of clinical applications for MV CBCT to grow as imaging technology continues to improve... - Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long?Mack Roach
Department of Radiation Oncology, University of California San Francisco, 94143 1708, USA
J Urol 170:S35-40; discussion S40-1. 2003..The results from recent randomized trials were used to identify subpopulations of patients most likely to benefit from long versus short-term hormonal therapy with external beam radiotherapy... - Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancerMack Roach
Department of Radiation Oncology, University of California, San Francisco, UCSF Mt Zion NCI Designated Comprehensive Cancer, 1600 Divisadero Street, San Francisco, CA 94143 1708, USA
Urol Clin North Am 31:353-66. 2004..Finally, the role of radiation protectors is beginning to be addressed. It is hoped that these advances will eliminate toxicity associated with radiotherapy and increase cure rates... - Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancerMichael J Zelefsky
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 59:1053-61. 2004..To report changing trends in external beam radiotherapy (EBRT) delivery practice for clinically localized prostate cancer as determined from the 1999 survey from the American College of Radiology National Patterns of Care Study... - Are lateral electronic portal images adequate for accurate on-line daily targeting of the prostate? Results of a prospective studyMichael W Lometti
Department of Radiation Oncology, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94143, USA
Med Dosim 33:22-9. 2008..In most circumstances, with exceptions such as morbidly obese patients, acquisition of only a LAT image for daily targeting of the prostate will provide adequate positional precision... - Influence of number of CAG repeats on local control in the RTOG 86-10 protocolMay Abdel-Wahab
Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL 33136, USA
Am J Clin Oncol 29:14-20. 2006..The purpose of this study was to determine if short-term androgen deprivation therapy (RT + HT) can improve outcome in patients with tumors with short CAG repeats (<19)... - Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastasesAndre Konski
Department of Radiation Oncology, Wayne State University School of Medicine, Barbara Ann Karmanus Cancer Center, Detroit, MI 48201, USA
Am J Clin Oncol 32:423-8. 2009..The purpose of the analysis was to determine whether multiple fraction treatment is cost-effective in treating patients with bone metastasis, by preventing further retreatment... - Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancerAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 70:671-7. 2008 - Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapyJoycelyn L Speight
Department of Radiation Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115 1708, USA
J Clin Oncol 25:987-95. 2007.... - Low-dose megavoltage cone-beam CT for radiation therapyJean Pouliot
Department of Radiation Oncology, University of California San Francisco, CA 94143 1708, USA
Int J Radiat Oncol Biol Phys 61:552-60. 2005.... - Goserelin acetate in combination with radiotherapy for prostate cancerMack Roach
Department of Radiation Oncology, University of California San Francisco, UCSF Comprehensive Cancer Center, San Francisco, California 94143 1708, USA
Expert Opin Pharmacother 8:257-64. 2007..The reduction in deaths from prostate cancer noted in the mid-1990s may largely be due to the early use of these agents in men with intermediate-to-high-risk disease... - Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancerTwyla R Willoughby
Department of Radiation Oncology, M.D. Anderson Cancer Center Orlando, Orlando, FL 32806, USA
Int J Radiat Oncol Biol Phys 65:528-34. 2006..Clinical evaluation of this novel 4D nonionizing electromagnetic localization system with transponders indicates a comparable localization accuracy to isocenter, (within 2 mm) compared with X-ray localization... - Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directionsJoycelyn L Speight
Department of Radiation Oncology, UCSF Mt Zion Comprehensive Cancer Center, 1600 Divisadero St H1031, Box 1708, San Francisco, CA 94143 1708, USA
J Clin Oncol 23:8176-85. 2005..This review is an evidence-based critique of the available treatment approaches considered for the optimal use of radiotherapy as definitive management of clinically localized PCa... - The evolving role of pelvic radiation therapyTerence Roberts
Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143-1708, USA
Semin Radiat Oncol 13:109-20. 2003..For most other solid tumors, the regional lymph nodes are routinely treated by some modality, so it is not surprising that WPRT might benefit a subset of high-risk patients... - Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imagingBarby Pickett
Department of Radiation Oncology, University of California, San Francisco, School of Medicine, 94143 1708, USA
Int J Radiat Oncol Biol Phys 59:665-73. 2004..To characterize the time to metabolic atrophy (TMA) after permanent prostate implantation (PPI) using combined MRI and magnetic resonance spectroscopic imaging (MRSI) compared with the time to prostate-specific antigen (PSA) nadir... - Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancerJanna Andrews
Department of Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, California 94143-1708, USA
Oncology (Williston Park) 19:29-36; discussion 36, 39, 43-4. 2005..The potential role of hormonal therapy in conjunction with brachytherapy without pelvic radiotherapy, is limited by inconclusive data and abbreviated follow-up times... - A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancerRobert Takamiya
Department of Radiation Oncology, University of California, San Francisco, CA 94143-1708, USA
Int J Radiat Oncol Biol Phys 56:1073-8. 2003..Patients with a definite increase in PSA slope are erroneously labeled disease free by the American Society for Therapeutic Radiology and Oncology consensus definition... - State-of-the-art radiotherapy in the management of clinically localized prostate carcinomaR Scott Bermudez
University of California, San Francisco, Department of Radiation Oncology, 1600 Divisadero Street, Suite number H1031, San Francisco, CA 94115, USA
Future Oncol 3:103-11. 2007..We have also learnt how to optimize the use of prostate-specific antigen to better determine success and failure following radiotherapy... - Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United StatesSteven J Frank
Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Brachytherapy 6:2-8. 2007..This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting... - Radiotherapy in the management of common genitourinary malignanciesJoycelyn L Speight
Department of Radiation Oncology, University of California San Francisco Comprehensive Cancer Center, H1031, 1600 Divisadero Street, San Francisco, CA 94143, USA
Hematol Oncol Clin North Am 20:321-46. 2006.... - (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging deviceJean Pouliot
Department of Radiation Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 56:862-6. 2003..Radiopaque gold markers can be implanted in the prostate to visualize its position on portal images during radiation therapy. This procedure assumes that the markers do not move within the prostate. In this work we test this assumptiom... - Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess responseEric J Small
Comprehensive Cancer Center, University of California, San Francisco, CA, USA
Semin Oncol 29:264-73. 2002.... - Interobserver variability leads to significant differences in quantifiers of prostate implant adequacyW Robert Lee
Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157 1030, USA
Int J Radiat Oncol Biol Phys 54:457-61. 2002..To compare the prostate gland volumes and subsequent quantifiers of implant adequacy determined by five separate brachytherapists on postimplant CT images performed 1 day after prostate brachytherapy... - Treatment margins and prostate brachytherapy: "size matters," but how much and where?Mack Roach
Departments of Radiation Oncology and Urology, University of California San Francisco, UCSF Mt Zion NCI Designated Comprehensive Cancer Center, 1600 Divisadero Street, Suite H 1031, San Francisco, CA 94143 1708, USA
Cancer J 10:158-9. 2004 - Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco 94115-1711, USA
J Urol 170:S3-5. 2003 - The effect of beam energy and number of fields on photon-based IMRT for deep-seated targetsAndrea Pirzkall
Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143 0226, USA
Int J Radiat Oncol Biol Phys 53:434-42. 2002..To examine the influence of energy and number of beams on nontarget dose when using intensity-modulated radiation therapy (IMRT) to treat deep-seated targets... - Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiativeDavid E Morris
Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA
Int J Radiat Oncol Biol Phys 62:3-19. 2005.... - Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesotheliomaTerry T Lee
Departments of Radiation Oncology, Surgery, and Medicine, University of California, San Francisco, Calif. 94115, USA
J Thorac Cardiovasc Surg 124:1183-9. 2002..CONCLUSIONS: Radical pleurectomy/decortication with aggressive radiotherapy with or without chemotherapy might offer an alternative treatment option to those who cannot tolerate extrapleural pneumonectomy... - Radiation medicine innovations for the new milleniumDwight E Heron
University of Pittsburgh School of Medicine Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
J Natl Med Assoc 95:55-63. 2003..PRINCIPAL CONCLUSIONS: Significant improvements in technique and equipment have firmly positioned radiotherapy as major artillery in the fight against both benign and malignant diseases... - Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10William U Shipley
Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 54:1302-10. 2002.... - "Supplemental beam" and prostate brachytherapy: a simple answer to a complicated question?Mack Roach
Int J Radiat Oncol Biol Phys 55:1162-3. 2003 - Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing"Mack Roach
Int J Radiat Oncol Biol Phys 57:907-9. 2003 - Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406Jeff M Michalski
Washington University Medical School, St Louis, MO 63110, USA
Semin Radiat Oncol 12:75-80. 2002..Clinical trials should use quality-of-life measures to determine that trade-offs between severity and rates of toxicity are acceptable to patients... - Is it time to change the standard of care from CT to MRI for defining the apex of the prostate to accomplish potency-sparing radiotherapy?Mack Roach
Int J Radiat Oncol Biol Phys 61:1-2. 2005 - Commentary on increased risk of biochemical and local failure in patients with a distended rectum on the planning CT for prostate cancer radiotherapyMack Roach
Int J Radiat Oncol Biol Phys 62:949-50. 2005 - Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen eraMark Soloway
Department of Urology, University of Miami School of Medicine, Miami, Florida 33136, USA
Cancer 104:2310-22. 2005..However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death... - Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trialsMack Roach
J Clin Oncol 26:3816-7; author reply 3817-8. 2008 - Quality of life and satisfaction with outcome among prostate-cancer survivorsJennifer S Yu
N Engl J Med 359:200; author reply 201-2. 2008 - Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomesNelson N Stone
Mount Sinai School of Medicine, New York, NY, USA
Int J Radiat Oncol Biol Phys 69:1472-7. 2007..To investigate the biochemical control rate in patients undergoing permanent prostate brachytherapy as a function of the biologically effective dose (BED) and risk group... - Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its applicationArjun Sahgal
Odette Cancer Center of the Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
Nat Clin Pract Urol 4:658-70. 2007..We also present our current policies in the treatment of prostate cancer at the University of California, San Francisco...